-
Pre-Made Chemogenetics AAV Vectors- Categories:
Aging & Neuroscience, Cell & Gene Therapy, Drug Discovery & Development, Gene Therapy, Recombinant Virus AAV, Vectors for Gene Therapy, Vectors, Viruses & mRNA
$0.00
-
Pre-Made Chemogenetics AAV Vectors
- Categories:
Aging & Neuroscience, Cell & Gene Therapy, Drug Discovery & Development, Gene Therapy, Recombinant Virus AAV, Vectors for Gene Therapy, Vectors, Viruses & mRNA
$0.00
Pertuzumab
Add to cart
Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.
[accordions]
[accordion title= “Animal Research“]
Objective: In vivo tumor growth inhibition studies. Formulation: saline. Dosages: 20 mg/kg, 40 mg/kg and 80 mg/kg
[/accordion]
[accordions]
[accordion title= “Chemical Properties“]
| Molecular Weight | 148 kDa |
| CAS No. | 380610-27-5 |
[/accordion]
[accordions]
[accordion title= “References and Literature“]
1. Sakai K, et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci.2007 Sep;98(9):1498-503.2. Yamashita-Kashima Y, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res. 2011 Aug 1;17(15):5060-70.3. Franklin MC, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004 Apr;5(4):317-28.
[/accordion]
